Italian 
English CASI CLINICI – Case Reports
Volume:
Biochimica Clinica 2013; 37(6) 504-507
Pubblicato on-line:
DOI:
Scarica in PDF:
Autenticazione richiesta
Utilità della misura dell’attività plasmatica di eparina-anti fattore Xa durante trattamento antitrombotico in gravidanza
AUTORI
Roberto Facchinetti
Laboratorio Analisi, Azienda Ospedaliera Universitaria di Verona, e Centro FCSA (Federazione dei centri per la diagnosi della trombosi e la sorveglianza delle terapie antitrombotiche) 186, Verona
Laboratorio Analisi, Azienda Ospedaliera Universitaria di Verona, e Centro FCSA (Federazione dei centri per la diagnosi della trombosi e la sorveglianza delle terapie antitrombotiche) 186, Verona
ABSTRACT
Usefulness of heparin-anti factor Xa assay during antithrombotic treatment in pregnancy
A case of successful pregnancy in a woman with previous episodes of unprovoked deep vein thrombosis treated with vitamin K antagonist (warfarin) therapy is described. As the patient became pregnant, warfarin therapy was immediately stopped and lowmolecular-weight heparin (LMWH) prophylaxis was started. In the second and third trimesters of pregnancy we observed an increase in body weight (from 64 to 80 kg) and in body mass index (from 21 to 26.4). During the pregnancy, we used the heparin-anti factor Xa assay (Anti-FXa) to monitor the LMWH treatment and to adjust the dosage in a increasing way. The Anti-FXa can be very useful in improving safety and efficacy of LMWH treatment in pregnancy.